Effect of zanamivir on duration and resolution of influenza symptoms

Clinical Therapeutics

Volumn 22, Issue 11, 2000, Pages 1294-1305

  Monto, Arnold S ^a   Moult, Andrew B ^b   Sharp, Stephen J ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antivirals; Influenza; Neuraminidase inhibitor; Zanamivir

Indexed keywords

AMANTADINE; OSELTAMIVIR; PLACEBO; SIALIDASE INHIBITOR; ZANAMIVIR;

AGED; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; RESPIRATORY SYSTEM; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 0033647050     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)83026-X     Document Type: Article

References (18)

1. Influenza: Quantifying morbidity and mortality
2. Efficacy of influenza vaccine in nursing homes: Reduction in illnesses and complications during an influenza A (H3N2) epidemic
3. Prevention control of influenza Recommendations of the Advisory Committee on ImmunizatiOn Practices (ACIP)
4. Implication of viral resistance to amantadine in control of influenza A
5. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families
6. Monitoring of viral susceptibility: New challenges with the development of influenza NA inhibitors
7. A novel approach to antiviral therapy for influenza
8. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies
9. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group
10. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B infections
11. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections
12. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomized, double-blind, placebo-controlled EUropean study
13. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: Pooled efficacy analysis
14. Zanamivir, a new targeted therapy in the treatment of influenza: A patient perspective assessed by questionnaire
15. Zanamivir: A review of clinical safety
16. Clinical signs and symptoms predicting influenza infection
17. Zanamivir for the treatment of clinically diagnosed influenza in clinical practice: Results of the Valuable-Insights-From Patients study